8 registrations that name gonadorelin as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 8 registrations
Status
Phase
8US sites across 5 states
1
2 to 4
5 to 19
20 or more
All 8 registrations
RecruitingNCT06179303
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2
University of Washington
About 60 people
Started Jul 22, 2024
In plain words A Phase 2 study of gonadorelin in people 18 and older, run by University of Washington. It plans to enroll about 60 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Unresectable HER2-Negative Breast Carcinoma; Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma.
Men or women with metastatic or locally advanced unresectable breast cancer
Histologically confirmed ER+ / HER2-negative, breast cancer who is a candidate for endocrine therapy with pathology from the primary tumor or metastatic/recurrent site.
In the case of bone biopsy which could yield false negative ER or PR status in patients with historically HR+ disease, a patient may be eligible if the treating physician and the study chair both agree that the patient is a candidate for…
Note that baseline PR status by IHC does not influence results of deltaFFNP-PET imaging.
15 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of hormone receptor positive (HR+), HER2 negative breast cancer. Abemaciclib blocks certain proteins, which may help keep tumor cells from growing. Endocrine therapy adds, blocks, or removes hormones that can cause cancer to grow. The full summary is on the listing.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 60 people
Started Mar 9, 2026
In plain words A Phase 2 study of gonadorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Metastatic Castration-resistant Prostate Cancer.
Age ≥ 18 years
Performance status ≤2.
Documented histologically confirmed adenocarcinoma of the prostate.
Baseline PSA ≥1.0 ng/ml.
16 more inclusion criteria and the exclusion criteria are on the listing.
The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alternating therapy.
Where, as registered
1 US site in 1 state.
RecruitingNCT07466498
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
Phase 2
Fred Hutchinson Cancer Center
About 60 people
Starts Nov 1, 2026 (estimated)
In plain words A Phase 2 study of gonadorelin in male participants 18 and older, run by Fred Hutchinson Cancer Center. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Castration-Sensitive Prostate Adenocarcinoma; Metastatic Castration-Sensitive Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8.
Must be willing to provide informed consent prior to any study specific procedures
Age ≥ 18 years
Documented histologically confirmed adenocarcinoma of the prostate
Patients must have evidence of newly diagnosed or relapsed metastatic hormone sensitive prostate cancer on CT, positron emission tomography (PET), MRI or bone scan
13 more inclusion criteria and the exclusion criteria are on the listing.
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving quality of life for patients with hormone sensitive prostate cancer that is newly diagnosed or that has come back after a period of improvement (recurrent) and has spread from where it first started (primary site) to other places in the body (metastatic). The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06059118
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 50 people
Started Oct 4, 2023
In plain words A Phase 2 study of gonadorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Prostate Cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.
Age ≥18 years.
Histologically-confirmed adenocarcinoma of the prostate.
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).
26 more inclusion criteria and the exclusion criteria are on the listing.
Asymptomatic patients with metastatic castrate resistant prostate cancer (mCRPC) without pain due to prostate cancer will be treated on an open label study to evaluate effectiveness of sequential treatment with the combination of difluoromethylornithine (DFMO) and high dose testosterone in sequence with enzalutamide to improve primary and secondary outcomes.
Where, as registered
1 US site in 1 state.
RecruitingNCT06922318
The COSMYC Trial (COmbined Suppression of MYC)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About 50 people
Started Aug 19, 2025
In plain words A Phase 2 study of gonadorelin in male participants 18 and older, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. It plans to enroll about 50 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Metastatic Castration-resistant Prostate Cancer.
Eastern Cooperative Oncology Group (ECOG) Performance status ≤2.
Age ≥18 years.
Histologically-confirmed adenocarcinoma of the prostate.
Treated with continuous androgen ablative therapy (either surgical castration or LHRH agonist/antagonist).
21 more inclusion criteria and the exclusion criteria are on the listing.
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigators also want to determine if dosing first with the combination of testosterone and ZEN-3694 may cause enzalutamide and ZEN-3694 to work more effectively.
Where, as registered
1 US site in 1 state.
RecruitingNCT07476001
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
Phase 2
H. Lee Moffitt Cancer Center and Research Institute
About 12 people
Started Mar 3, 2026
In plain words A Phase 2 study of gonadorelin in male participants 18 and older, run by H. Lee Moffitt Cancer Center and Research Institute. It plans to enroll about 12 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 and older. Conditions: Metastatic Castration-resistant Prostate Cancer.
Participants must have histologically or cytologically confirmed prostate cancer that has progressed to mCRPC with no grade 2 or above cancer related symptoms.
Participants need to have either PSA or imaging progression at castrate level of serum testosterone (i.e. <50ng/dl).
Participants need to have a positive PSMA PET scan and deem eligible for PSMA-617.
Allowable prior therapies: Prior treatment with one line of ARPI. Patients need to be on ARPI for at least 4 weeks to be considered one line of therapy. Prior treatment with sipuleucel-T for mCRPC.
6 more inclusion criteria and the exclusion criteria are on the listing.
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Where, as registered
1 US site in 1 state.
RecruitingNCT06382948
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3
MedSIR
About 300 people
Started Dec 5, 2024
In plain words A Phase 3 study of gonadorelin in people 18 and older, run by MedSIR. It plans to enroll about 300 people at 104 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation.
Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.
Female or male patients ≥ 18 years of age at the time of signing ICF.
Pre- or perimenopausal women, who do not meet the criteria for post-menopausal status (defined in continuation) and men must be concurrently receiving a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum…
Age ≥ 60 years;
22 more inclusion criteria and the exclusion criteria are on the listing.
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated. Patients will be treated with elacestrant, a compound that acts as a selective estrogen receptor degrader, and everolimus (or placebo), a kinase inhibitor indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer. The full summary is on the listing.
Where, as registered
No US site; Spain (42), France (12), Italy (12), Greece (10), Germany (7), Czechia (6), United Kingdom (6), Brazil (5), Austria (4).
RecruitingNCT04390646
GnRH Therapy on Cognition in Down Syndrome
Phase 2 and 3
Nelly Pitteloud
About 56 people
Started Aug 27, 2020
In plain words A Phase 2 and 3 study of gonadorelin in people 16 to 50, run by Nelly Pitteloud. It plans to enroll about 56 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 16 to 50. Conditions: Down Syndrome; Cognitive Decline; Alzheimer Disease, Early Onset; Olfaction Disorders.
Diagnosis of trisomy 21
Verbal expression (ability to follow the procedures of the study)
Consent to a non-hormonal contraception during the whole duration of the study For women: intra-uterine device with copper, a prior tubal ligation or condoms for the partner For men: condoms or vasectomy
The exclusion criteria are on the listing.
What it tests, as registered
GnRH, gonadorelin acetate; 0.9% NaCl
Registered summary
Down syndrome (DS) is the most common chromosomal disorder; with the increasing life expectancy, about 80% of DS adults reach age 65 years old. Early Alzheimer's disease (AD) is the most common cause of death within this population. DS individuals already show AD neuropathology by the age of 30, while it becomes clinically recognized in their late forties. DS subjects also exhibit olfaction defects in adulthood. To date, there is no treatment available for the cognitive or olfactory defects in DS. The full summary is on the listing.